Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination antifungals: an update.

Brahm H Segal1, William J Steinbach

  • 1Roswell Park Cancer Institute, Division of Infectious Diseases, Elm & Carlton Streets, Buffalo, NY 14263, USA. brahm.segal@roswellpark.org

Expert Review of Anti-Infective Therapy
|October 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional Roles of Autophagy in Fungi.

Journal of fungi (Basel, Switzerland)·2026
Same author

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

Cancer immunology research·2026
Same author

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

International journal of cancer·2026
Same author

Incidence Rates of Candida Bloodstream Infections in Patients With Malignancies in a Comprehensive Cancer Centre.

Mycoses·2025
Same author

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients.

Cancer research communications·2025
Same author

Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents.

Nature communications·2025
Same journal

Complicated urinary tract infections: evolving definitions, clinical burden, and treatment landscape amid antimicrobial resistance.

Expert review of anti-infective therapy·2026
Same journal

The changing picture of community acquired urinary tract infections in the US: a daunting prospect.

Expert review of anti-infective therapy·2026
Same journal

Study of prescription-indication of antivirals for herpesviruses in a Colombian population: a cross-sectional study.

Expert review of anti-infective therapy·2026
Same journal

Effectiveness and safety of eravacycline-based regimens for resistant <i>Acinetobacter baumannii</i> infections: a systematic review and meta-analysis.

Expert review of anti-infective therapy·2026
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
Same journal

Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disease as an early neuroinflammatory state.

Expert review of anti-infective therapy·2026
See all related articles

Combination antifungal therapies show promise for invasive fungal infections, but clinical evidence is limited, especially for Candida and Aspergillus species. Further research is needed to optimize treatment strategies beyond cryptococcal meningitis.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) are significant causes of illness and death in vulnerable patients.
  • While antifungal drug options have expanded, optimal treatments for many IFIs are still lacking.
  • Genomic advancements offer new targets for antifungal drug development.

Purpose of the Study:

  • To review current knowledge on combination antifungal therapy for IFIs.
  • To focus on Cryptococcus neoformans, Candida, and Aspergillus species.
  • To identify gaps in understanding and guide future research.

Main Methods:

  • Review of in vitro studies.
  • Analysis of animal model data.
  • Examination of clinical trial insights.

Related Experiment Videos

Main Results:

  • Combination therapy is primarily supported by randomized clinical trials for cryptococcal meningitis.
  • Limited clinical trial data exists for combination therapies against Candida and Aspergillus.
  • In vitro and animal models provide valuable, though often preliminary, insights.

Conclusions:

  • Combination antifungal therapy is a promising area, particularly with new drug targets emerging.
  • More robust clinical trials are essential to validate combination strategies for common IFIs.
  • Future treatments may involve combining existing antifungals with cell-stress pathway inhibitors.